Targovax granted European patent for cancer immunotherapy

By The Science Advisory Board staff writers

October 12, 2020 -- The European Patent Office has granted a patent to clinical stage immuno-oncology firm Targovax for use of its modified adenovirus in combination with checkpoint inhibitors for cancer therapeutics.

Modified oncolytic adenovirus ONCOS-102 is Targovax's leading product candidate. The patent to use ONCOS-102 with programmed cell death 1 (PD-1) checkpoint inhibitors strengthens the company's intellectual property portfolio, according to Torbjørn Furuseth, Targovax's chief financial officer.

Targovax engineered the virus to selectively infect cancer cells and aid the immune system in combating cancer. The candidate produced encouraging data in part one of a 2019 clinical trial on patients with melanoma, according to the company. Data from part two of the clinical trial is expected later in 2020. The company's lead candidate is also be evaluated in clinical trials for patients with mesothelioma, melanoma, ovarian, and colorectal cancers as both a monotherapy and in combination with other cancer treatments.

Oblique, Targovax partner on anticancer treatment
Oblique Therapeutics and Targovax are partnering on anticancer treatment by combining their Oncos and Abiprot offerings.
Innovations in synthetic chemistry help identify new cancer therapies
The pathway to discovering and developing cancer therapies is not always linear, but well-designed models incorporating smart chemical innovations can...
Lyell and Pact partner on T-cell therapy
Lyell Immunopharma and Pact Pharma have formed a strategic partnership to jointly develop and test a next-generation personalized anticancer T-cell therapy...
CNS Pharma partners with MD Anderson
Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center...
EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter